Evercore ISI analyst Gavin Clark-Gartner downgraded Rallybio (RLYB) to In Line from Outperform and removed its prior $8 price target after the company announced the discontinuation of its RLYB212 program, which was undergoing development for the prevention of fetal and neonatal alloimmune thrombocytopena.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLYB:
- Rallybio downgraded to Neutral from Buy at H.C. Wainwright
- Citizens JMP downgrades Rallybio on RLYB212 discontinuation
- Rallybio downgraded to Market Perform from Outperform at Citizens JMP
- Rallybio discontinues RLYB212 program
- Rallybio’s Promising Developments and Financial Stability Justify Buy Rating